Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

News Conference News AHA 2020

Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF

November 16, 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

News Conference News AHA 2020

Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF

November 13, 2020

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

News Daily News

VERTIS CV: Ertugliflozin Meets Noninferiority Endpoint but Misses Other Marks

Michael O'Riordan

September 24, 2020

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

News Daily News

Recurrent Events After MI Show Enduring Gender, Racial Gaps in Care

September 22, 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

August 30, 2020

US Mortality Rates for CVD Have Stalled as Racial Disparities Widen

News Daily News

US Mortality Rates for CVD Have Stalled as Racial Disparities Widen

Yael L. Maxwell

August 19, 2020

Too Many HF Trial Results Underreported or Never Published

News Daily News

Too Many HF Trial Results Underreported or Never Published

June 23, 2020

MitraClip Cuts Death, HF Hospitalization Across NYHA Class: COAPT

News Conference News TVT 2020

MitraClip Cuts Death, HF Hospitalization Across NYHA Class: COAPT

Michael O'Riordan

June 21, 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

News Conference News HRS 2020

Subcutaneous ICD Holds Up Well Against Transvenous Devices

May 13, 2020

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

News Daily News

COVID-19, ACE Inhibitors, and ARBs: Multiple Studies Show No Increased Risk

Michael O'Riordan

May 05, 2020

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.